MINITRAN
Clinical safety rating
cautionComprehensive clinical and safety monograph for MINITRAN (MINITRAN).
Nitroglycerin is converted to nitric oxide (NO) in vascular smooth muscle, which activates guanylyl cyclase, increasing cGMP levels. This leads to dephosphorylation of myosin light chains and vasodilation, particularly in venous capacitance vessels and coronary arteries, reducing preload and afterload.
| Metabolism | Rapidly metabolized in the liver by glutathione-organic nitrate reductase, with minor contributions from vascular wall and RBC metabolism. Metabolites include 1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate. |
| Excretion | Primarily renal excretion of inactive metabolites; less than 1% excreted unchanged. Biliary/fecal elimination is minimal. |
| Half-life | Terminal half-life is approximately 1-4 minutes for nitroglycerin; clinical effect duration is longer due to tissue distribution. |
| Protein binding | Approximately 60% bound to plasma proteins (albumin). |
| Volume of Distribution | Vd is about 3 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Transdermal: approximately 70-80% of the dose reaches systemic circulation. |
| Onset of Action | Transdermal: 30-60 minutes; therapeutic effect delayed due to slow absorption. |
| Duration of Action | Transdermal: 8-12 hours; requires daily patch-off period to prevent tolerance. |
| Molecular Weight | 227.09 |
Minitran (nitroglycerin transdermal) is applied as a transdermal patch. Initial dose: 0.2-0.4 mg/hour applied once daily. Titrate based on response and tolerance. Maximum dose: 0.8 mg/hour. The patch is worn for 12-14 hours daily with a 10-12 hour nitrate-free interval to prevent tolerance.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | No specific dose adjustment required for renal impairment. However, patients with severe renal insufficiency (CrCl <30 mL/min) may have increased risk of adverse effects; monitor closely. |
| Liver impairment | No specific dose adjustment recommended for Child-Pugh A or B. For Child-Pugh C (severe hepatic impairment), consider reducing dose due to reduced metabolism and increased risk of hypotension; use with caution. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. Use only under expert guidance. Typical initial dose: 0.1-0.2 mg/hour transdermally, titrated cautiously based on clinical response and tolerance. |
| Geriatric use | Elderly patients may be more sensitive to the hypotensive effects. Start at the lower end of dosing range (0.2 mg/hour) and titrate slowly. Monitor blood pressure and heart rate regularly. |
| 1st trimester | Avoid use. Nitroglycerin may cause fetal bradycardia and hypotension. Animal studies have shown fetal harm. Use only if clearly needed. |
| 2nd trimester | Use with caution. Can cause maternal hypotension and reduced uterine blood flow. Monitor fetal heart rate. |
| 3rd trimester | Use with caution. Risk of maternal hypotension and fetal distress. May inhibit uterine contractions and prolong labor. |
Clinical note
Comprehensive clinical and safety monograph for MINITRAN (MINITRAN).
| Placental transfer | Nitroglycerin crosses the placenta readily based on animal studies. Human data limited; no specific transfer rate quantified. |
| Breastfeeding | Nitroglycerin is excreted into breast milk in small amounts. The American Academy of Pediatrics considers it compatible with breastfeeding. However, monitor infant for hypotension, methemoglobinemia, and dizziness. Use lowest effective dose. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Category C. Animal studies show fetal harm; no adequate human studies. Use only if maternal benefit outweighs risk. First trimester: possible teratogenic effects. Second/third trimesters: risk of fetal bradycardia, hypotension, and decreased placental perfusion. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of hypotension. Fetal heart rate monitoring recommended during administration. |
| Fertility Effects | No specific data on fertility effects in humans. Animal studies show no adverse effects on fertility. |
■ FDA Black Box Warning
Do not use MINITRAN in patients taking phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) as this can cause severe hypotension. Additionally, MINITRAN should not be used in patients with early myocardial infarction or severe anemia.
| Serious Effects |
Hypersensitivity to nitroglycerin or any componentSevere anemiaIncreased intracranial pressure (e.g., head trauma, cerebral hemorrhage)Constrictive pericarditis, pericardial tamponadeConcurrent use with phosphodiesterase-5 inhibitors (sildenafil, vardenafil, tadalafil) within 24-48 hoursHypotension (systolic blood pressure <90 mmHg)Acute myocardial infarction with right ventricular infarction or cardiogenic shock
| Precautions | Hypotension; paradoxical bradycardia; tolerance (need for nitrate-free interval); exacerbation of angina with abrupt discontinuation; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy. |
| Food/Dietary | Concurrent use of alcohol can cause vasodilation and hypotension. Limit or avoid alcohol. No specific food restrictions. |
| Clinical Pearls | MINITRAN (nitroglycerin transdermal) is used for angina prophylaxis, not acute attacks. Apply to hairless area, rotate sites, and remove for 12-14 hours daily to prevent tolerance. If headache occurs, reduce dose or use acetaminophen. Do not discontinue abruptly to avoid rebound ischemia. |
| Patient Advice | Apply patch to clean, dry, hairless skin on chest, arm, or back; rotate sites daily. · Remove patch after 12-14 hours to prevent tolerance; apply new patch at same time next morning. · Do not use for acute angina; use sublingual nitroglycerin instead. · Avoid alcohol and erectile dysfunction drugs like sildenafil; can cause severe hypotension. · Headache may occur; use acetaminophen or reduce dose; do not stop abruptly. |
Loading safety data…